Concept:
Neonatal cholestasis impairs the normal delivery of bile salts into the duodenal lumen, disrupting micellar solubilization and absorption of fat-soluble vitamins (A, D, E, and K).
Vitamin K deficiency rapidly impairs hepatic gamma-carboxylation of coagulation factors II, VII, IX, and X, predisposing the infant to coagulopathy and life-threatening intracranial hemorrhage.
Explanation:
• In chronic cholestatic liver disease, intestinal absorption of dietary fat-soluble vitamins is profoundly reduced.
• Standard pediatric gastroenterology and hepatology consensus guidelines (ESPGHAN/NASPGHAN) mandate regular oral supplementation with fat-soluble vitamins for all cholestatic infants.
• Because of poor intestinal absorption, standard physiological replacement doses are inadequate; high-dose oral water-soluble micellar preparations are required.
• The recommended routine maintenance dosage for Vitamin K in pediatric cholestasis is $2.5\text{ to 5\text{ mg administered orally daily}$}, or $5\text{ mg}$ twice weekly, or periodic parenteral doses ($2.5\text{--}5\text{ mg}$ IM/SC every $1\text{--}4\text{ weeks}$) if oral absorption is severely compromised.
• Daily oral supplementation ensures consistent maintenance of prothrombin complex activity and prevents coagulopathy during periods of poor dietary intake.
Final Answer:
The recommended oral vitamin K maintenance supplementation in an infant with cholestasis is 2.5–5 mg daily.